Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Pre-hypertension, Cardiovascular Diseases
Interventions: Watermelon Flesh Dose 1, Watermelon Flesh Dose 2, Control; Other
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension, Pregnancy-Induced
Interventions: Mobile Health; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Preeclampsia
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Preeclampsia With Severe Features, Chronic Hypertension in Obstetric Context
Interventions: Experimental dosing of labetalol, Standard dosing of labetalol; Drug · Other
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Albany, New York

Conditions: Hypertension, Pulmonary
Interventions: Ambrisentan - low dose, Ambrisentan - high dose; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 8 Years to 18 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: Preeclampsia, Severe Preeclampsia, Eculizumab, HELLP, HELLP Syndrome, HELLP Syndrome Second Trimester, Pregnancy Related, AHUS, PNH, Complement Regulatory Factor Defect, Complement Abnormality, HELLP Syndrome Third Trimester
Interventions: Eculizumab; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 13 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pre-Eclampsia, Severe, Pregnancy
Interventions: Noninvasive finger plethysmographic cardiac output monitoring, Standard transthoracic echocardiographic assessment; Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Medication Adherence, Hypertension
Interventions: Scorecard, Social norms, Messenger effects, Processing fluency; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years to 79 Years
Enrollment: 65,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Coronary Disease, Hypertension
Interventions: Not listed
Lead sponsor: Tulane University; Other
Eligibility: Not listed
Enrollment: 11,737 participants
Timeline: 1973 – 2040
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions: Free Eye Screenings, Enhanced Intervention, Usual Care; Other
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years and older
Enrollment: 906 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Ocular Hypertension
Interventions: Fixed-Combination Bimatoprost/Brimonidine, Bimatoprost Ophthalmic Solution 0.01%, Vehicle Ophthalmic Solution, Brimonidine Tartrate Ophthalmic Solution 0.2%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 40 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: COPD, Pulmonary Hypertension, Right Ventricular Dysfunction, Exercise, Exercise Training
Interventions: Exercise; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Open Angle Glaucoma
Interventions: Transluminal viscoelastic delivery and trabeculotomy; Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 15
States / cities: Dothan, Alabama • Lake Havasu City, Arizona • Fayetteville, Arkansas + 12 more

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Placebo matching Dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 2,245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 155
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 117 more

Conditions: Hypertension
Interventions: valsartan plus hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Remote Visit; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pulmonary Arterial Hypertension
Interventions: AIR001; Drug
Lead sponsor: Aires Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 17
States / cities: La Jolla, California • Torrance, California • Aurora, Colorado + 12 more

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost, Timolol 0.5%, Placebo Ocular Insert, Placebo Eye Drops; Drug · Device
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 10
States / cities: Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 7 more

Conditions: Pregnancy, Eclampsia
Interventions: CytoCam, NIRS Artinis PortaLite with OxySoft softwear; Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Atherosclerosis, Congestive Heart Failure, Left Ventricular Hypertrophy, Diabetes Mellitus, Hypertension, Obesity, Metabolic Syndrome X, Myocardial Infarction
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 35 Years to 70 Years
Enrollment: 3,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension
Interventions: EngageRx_SMBP; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypertension
Interventions: Ambrisentan 5 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Preeclampsia
Interventions: Aspirin; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes, Hypertension, Hypercholesterolemia
Interventions: Pharmacist calls patient unless physician cancels call, Patient nonadherence information sent to physician, Pharmacist calls patient if physician requests call, Doctor receives information and may be allowed certain actions; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 2,697 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Providence, Rhode Island

Search by objective public record fields.

Watermelon Dose Response Blood Pressure Study

Postpartum Hypertension: Remote Patient Monitoring

The Study of Cardiovascular Outcomes in Women With Preeclampsia Using Echocardiography: The SCOPE Study

Acute Control of Chronic Hypertension

Efficacy and Safety of Ambrisentan in Children 8-18yrs

Complement Regulation to Undo Systemic Harm in Preeclampsia

Finger Plethysmography to Predict Fluid Responsiveness in Healthy Pregnancy and Severe Preeclampsia

Social Norms, Messengers, and Processing Fluency to Increase Hypertension Medication Adherence

Bogalusa Heart Study

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients With Chronic Obstructive Pulmonary Disease

Study of OMNI System in OAG (GEMINI)

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.

Remote Physician Care for Home Hospital Patients

Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05

Dose-Ranging Study of the Bimatoprost Ocular Insert

Microcirculatory and Tissue and Cerebral Oxygenation in Preeclampsia and Normal Pregnancy: An Observation Study

Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study Cohort

EngageRx With Integrated Self-Measurement of Blood Pressure

A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Predictors of Aspirin Failure in Preeclampsia Prevention

Pharmacy Home Adherence Reporting and Monitoring Outcomes Study